ClinicalTrials.gg
CompletedNCT06621316Updated Aug 24, 2026

A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects

A Phase 1/2 interventional study of HRS-7535 Tablet and Placebo in Overweight or Obesity, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-24.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 13 under way, 4 of them phase 3. Obesity · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
18th of 24
74 · median 130
Started
2024
with 3 others
Phase 1/2
Only one
of the 24
Registered
7th of 24
by date

Among the 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd., this one is the 18th largest by enrollment, is one of 4 that started in 2024, is the only one in phase 1/2, and was the 7th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of HRS-7535 tablet in obese subjects.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

This study's enrollment of 74 is above the median of 67 across 9,027 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. At screening: ≥30 kg/m2.
  3. Have been controlled by diet and exercise for 3 months or more before screening, and the change in body weight in the past 3 months is less than 5%.
  4. Male and female subjects of through signing the informed consent form to 1 month after the last dose have no family plans and must use highly effective , and female participants of childbearing potential also must have no plans to donate eggs (male participants must have no plans to be sperm donors); Female subjects of childbearing potential must have a serum pregnancy test within 7 days prior to the date of randomization, including the day of randomization.

Exclusion criteria

Exclusion Criteria:

  1. abnormalities in relevant laboratory tests at screening.
  2. The results of the at screening show clinically significant abnormalities that may affect the safety of the subject, including but not limited to myocardial infarction, severe arrhythmias such as supraventricular tachycardia, atrial fibrillation, atrial flutter, second- or third-degree atrioventricular block, etc.
  3. Heart rate or pulse > 100 beats per minute or ECG >450 ms at screening.
  4. The PHQ-9 score ≥ 15 points.
  5. Poor blood pressure control at screening.
  6. Presence or history of endocrine disease that may significantly affect body weight at screening.
  7. History of diabetes mellitus.
  8. Within 6 months prior to screening, the subject has the following diseases of clinical significance: including but not limited to neurological, psychiatric, cardiovascular, endocrine, gastrointestinal, respiratory, urinary, blood, immune system and other diseases, which may interfere with the trial results or pose additional risks to the administration of the study drug as judged by the investigator.
  9. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
  10. Previous or known history of acute or chronic pancreatitis, history of cholecystitis or history of gallstones, chronic malabsorption syndrome or cholestasis.
  11. Severe cardiovascular and cerebrovascular diseases within 6 months prior to screening, including but not limited to: heart failure ( grade II-IV), angina, stroke or , myocardial infarction, severe arrhythmia, or coronary artery bypass grafting or percutaneous coronary intervention, etc.; and/or planned revascularization of the coronary arteries, carotid arteries, or peripheral arteries at the time of screening.
  12. Any malignant tumor of any organ system within 5 years, regardless of whether there is evidence of local recurrence or , except for cured local cancer, such as: local basal cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the prostate.
  13. Those who have had serious infections, severe trauma, major and medium-sized surgeries, or planned to undergo surgery during the trial within 6 months prior to screening.
  14. Those with or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia or other more serious mental illness; or mentally incapacitated or with a language impairment that is unable to fully understand the trial protocol or is unwilling to collaborate with study center staff.
  15. Presence of a history of acute or chronic hepatitis or other serious liver disease other than non-alcoholic fatty liver disease.
  16. Presence of any blood disorder (e.g., hemolytic anemia, sickle cell disease, etc.) that may interfere with detection.
  17. diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis).
  18. Use of medications or treatments that may cause significant weight gain or loss within 2 months prior to screening:

    • (short-term systemic use\< 7 days or topical, inhaled, intraocular and nasal administration);
    • tricyclic antidepressants, atypical antipsychotics and mood stabilizers (such as imipramine, chlorpromazine, amitriptyline, mirtazapine, clozapine, olanzapine, paroxetine, phenelzine, thioridazine, valproic acid and its derivatives, lithium salts, etc.);
    • Orlistat, GLP-1 receptor agonists, or incretins, or other weight-loss therapies other than diet and exercise (including GLP-1 receptor agonists, multi-targeted agents);
    • Other medications or treatments that may significantly affect blood sugar or body weight (eg, metformin, SGLT-2 inhibitors, etc.).
  19. Undergoing or planning bariatric surgery or weight-loss therapy based on endoscopy and/or medical devices, etc. during the study period (except for a history of liposuction surgery greater than 1 year).
  20. Prior discontinuation of GLP-1 receptor agonist-containing agents for safety and/or tolerability reasons.
  21. whichever is longer: Participated in a clinical trial of any drug or medical device within 3 months prior to screening or is still within 5 half-lives of the drug. Participation in clinical trials is defined as: signing and using investigational drugs (including placebo) or investigational medical devices; Participated in clinical trials of drugs containing GLP-1 receptor agonists (including placebo) within 6 months prior to screening.
  22. Known or suspected to GLP-1 receptor agonist drugs, the investigational drug or its components, or its .
  23. Addiction to tobacco and alcohol.
  24. Those who have a history of blood donation or blood loss of ≥400ml within 3 months before screening or have received blood transfusion within 2 months.
  25. Subjects who are mentally incapacitated or have language impairment who cannot fully understand or participate in the trial process.
  26. Females who are pregnant, lactating, planning to become pregnant during the trial, or subjects of who are unwilling to use highly effective during the trial period (starting from signing the informed consent form) and within 1 month after the last dose.
  27. Inability to tolerate venipuncture blood sampling or needle phobia.
  28. Any condition judged by the investigator to be unsuitable to participate in this clinical trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Treatment group A

    HRS-7535 Tablet at dose level 1

    Drug: HRS-7535 Tablet

  • Experimental
    Treatment group B

    HRS-7535 Tablet at dose level 2

    Drug: HRS-7535 Tablet

  • Experimental
    Treatment group C

    HRS-7535 Tablet at dose level 3

    Drug: HRS-7535 Tablet

  • Experimental
    Treatment group D

    HRS-7535 Tablet at dose level 4

    Drug: HRS-7535 Tablet

  • Placebo comparator
    Treatment group E

    Placebo at dose level 1

    Drug: Placebo

  • Placebo comparator
    Treatment group F

    Placebo at dose level 2

    Drug: Placebo

  • Placebo comparator
    Treatment group G

    Placebo at dose level 3

    Drug: Placebo

  • Placebo comparator
    Treatment group H

    Placebo at dose level 4

    Drug: Placebo

  • Experimental
    Treatment group I

    HRS-7535 Tablet at dose level 1 or level 2 or level 3 or level 4.

    Drug: HRS-7535 Tablet

  • Experimental
    Treatment group J

    HRS-7535 Tablet at dose level 1 or level 2 or level 3 or level 4.

    Drug: HRS-7535 Tablet

  • Placebo comparator
    Treatment group K

    Placebo at dose level 1 or level 2.

    Drug: Placebo

  • Placebo comparator
    Treatment group L

    Placebo at dose level 1 or level 2.

    Drug: Placebo

Interventions

  • at multiple dose levels

  • DrugPlacebo

    at multiple dose levels (matching active arm HRS-7535 Tablet)

07

What researchers measure

Primary outcomes

  1. Number of Adverse Events

    Time frame: 24 weeks

Secondary outcomes

  1. Pharmacokinetic endpoint: Concentration of HRS-7535 in plasma

    Time frame: 24 weeks

  2. Change in fasting weight at week 24

    Time frame: 24 weeks

  3. Change in waist circumference at week 24

    Time frame: 24 weeks

08

Study locations

1 site
  • Peking University Peoples Hospital
    Beijing, Beijing Municipality 010000, China
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jul 2025, 8 months.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2024
First posted
Oct 1, 2024
StartActual
Oct 30, 2024
Primary completionActual
Jul 14, 2025
CompletionActual
Jul 14, 2025
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06621316
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Oct 30, 2024
Primary completion
Jul 14, 2025
Completion
Jul 14, 2025
Last update
Aug 24, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-7535

Start the discussion